Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice.

PubWeight™: 1.67‹?› | Rank: Top 3%

🔗 View Article (PMC 3224595)

Published in Mol Neurodegener on June 06, 2011

Authors

Cristian A Lasagna-Reeves1, Diana L Castillo-Carranza, Urmi Sengupta, Audra L Clos, George R Jackson, Rakez Kayed

Author Affiliations

1: George P, and Cynthia Woods Mitchell Center for Neurodegenerative Diseases, Departments of Neurology, and Neuroscience and Cell Biology, The University of Texas Medical Branch, Galveston, TX 77555-1045, USA. rakayed@utmb.edu.

Articles citing this

Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 1.77

Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med (2015) 1.66

The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59

α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42

Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain (2013) 1.40

Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol (2011) 1.30

Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A (2013) 1.16

GSK3 and Alzheimer's Disease: Facts and Fiction…. Front Mol Neurosci (2011) 1.09

The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05

The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev (2013) 1.05

Formation and propagation of tau oligomeric seeds. Front Neurol (2013) 1.04

Are tau aggregates toxic or protective in tauopathies? Front Neurol (2013) 1.03

Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci (2012) 1.02

Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies. J Biol Chem (2013) 1.01

Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol (2013) 0.99

Tangles, Toxicity, and Tau Secretion in AD - New Approaches to a Vexing Problem. Front Neurol (2013) 0.96

Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet (2014) 0.95

Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs. Front Neurol (2013) 0.94

A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nat Commun (2015) 0.91

Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain (2012) 0.90

Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun (2014) 0.89

Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by Tau protein. J Biol Chem (2011) 0.89

Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol (2013) 0.89

TOC1: characterization of a selective oligomeric tau antibody. J Alzheimers Dis (2013) 0.89

Characteristics of tau oligomers. Front Neurol (2013) 0.89

Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease. J Neurochem (2015) 0.88

Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J (2015) 0.88

Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis (2012) 0.88

Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer's disease? Oxid Med Cell Longev (2014) 0.88

Bimolecular fluorescence complementation; lighting-up tau-tau interaction in living cells. PLoS One (2013) 0.87

Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. J Neurotrauma (2016) 0.87

Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci (2014) 0.86

Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicity. J Biol Chem (2014) 0.86

Alzheimer disease: a tale of two prions. Prion (2012) 0.86

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun (2014) 0.85

Molecular insights into the reversible formation of tau protein fibrils. Chem Commun (Camb) (2013) 0.84

Using intramolecular disulfide bonds in tau protein to deduce structural features of aggregation-resistant conformations. J Biol Chem (2012) 0.84

Tau in MAPK activation. Front Neurol (2013) 0.83

Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. Am J Pathol (2016) 0.81

Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss. Sci Rep (2016) 0.81

The pathophysiology of repetitive concussive traumatic brain injury in experimental models; new developments and open questions. Mol Cell Neurosci (2015) 0.80

Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiol Aging (2014) 0.80

Roles of tau protein in health and disease. Acta Neuropathol (2017) 0.80

Herpes Simplex Virus type-1 infection induces synaptic dysfunction in cultured cortical neurons via GSK-3 activation and intraneuronal amyloid-β protein accumulation. Sci Rep (2015) 0.79

Potential mechanisms and implications for the formation of tau oligomeric strains. Crit Rev Biochem Mol Biol (2016) 0.79

Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis. J Neurosci (2016) 0.79

Increased tau phosphorylation and tau truncation, and decreased synaptophysin levels in mutant BRI2/tau transgenic mice. PLoS One (2013) 0.79

When amyloids become prions. Prion (2014) 0.79

Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease. Front Cell Neurosci (2015) 0.78

Identification of Novel Tau Interactions with Endoplasmic Reticulum Proteins in Alzheimer's Disease Brain. J Alzheimers Dis (2015) 0.78

The Metamorphic Nature of the Tau Protein: Dynamic Flexibility Comes at a Cost. Front Neurosci (2016) 0.78

Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies. J Neuroimmune Pharmacol (2015) 0.78

Ameliorative Effects of Antioxidants on the Hippocampal Accumulation of Pathologic Tau in a Rat Model of Blast-Induced Traumatic Brain Injury. Oxid Med Cell Longev (2015) 0.78

Tau mutant A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and reduced lifespan independently of aggregation in a C. elegans Tauopathy model. Mol Neurodegener (2016) 0.78

Glucose deficit triggers tau pathology and synaptic dysfunction in a tauopathy mouse model. Transl Psychiatry (2017) 0.78

Rescue from tau-induced neuronal dysfunction produces insoluble tau oligomers. Sci Rep (2015) 0.77

Altered Cholesterol Intracellular Trafficking and the Development of Pathological Hallmarks of Sporadic AD. J Parkinsons Dis Alzheimers Dis (2015) 0.76

In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis (2016) 0.76

Reelin Proteolysis Affects Signaling Related to Normal Synapse Function and Neurodegeneration. Front Cell Neurosci (2016) 0.76

Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease. Eur J Neurosci (2016) 0.76

Tau physiology and pathomechanisms in frontotemporal lobar degeneration. J Neurochem (2016) 0.76

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target? Immunotargets Ther (2013) 0.75

The Role of the Carboxyl-Terminal Sequence of Tau and MAP2 in the Pathogenesis of Dementia. Front Mol Neurosci (2016) 0.75

Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag. Protein Expr Purif (2016) 0.75

NDUFA12L mitochondrial complex-I assembly factor: Implications for taupathies. Appl Transl Genom (2015) 0.75

PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo. PLoS One (2015) 0.75

Synaptic failure: The achilles tendon of sphingolipidoses. J Neurosci Res (2016) 0.75

Cell-based Models To Investigate Tau Aggregation. Comput Struct Biotechnol J (2014) 0.75

Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Acta Neuropathol (2016) 0.75

Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. Front Aging Neurosci (2017) 0.75

Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. J Alzheimers Dis (2016) 0.75

Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe. Am J Nucl Med Mol Imaging (2013) 0.75

Reduced Gliotransmitter Release from Astrocytes Mediates Tau-Induced Synaptic Dysfunction in Cultured Hippocampal Neurons. Glia (2017) 0.75

Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation. Neurobiol Dis (2017) 0.75

Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits. Proc Natl Acad Sci U S A (2017) 0.75

Human cyclophilin 40 unravels neurotoxic amyloids. PLoS Biol (2017) 0.75

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies. Aging Dis (2017) 0.75

Amyloidogenesis of Tau protein. Protein Sci (2017) 0.75

Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early Alzheimer's disease. Synapse (2017) 0.75

Articles by these authors

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14

Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 4.23

Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42

Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem (2002) 3.37

Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A (2004) 2.32

Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2006) 2.27

Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci (2009) 2.11

Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 1.77

Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet (2011) 1.72

Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70

Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol (2006) 1.64

Preparation and characterization of neurotoxic tau oligomers. Biochemistry (2010) 1.53

Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes (2007) 1.52

Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2005) 1.49

Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab (2006) 1.47

Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry (2007) 1.44

Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest (2006) 1.43

A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J Neurosci (2007) 1.40

Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci (2014) 1.28

ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem (2006) 1.28

Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem (2011) 1.24

A Drosophila model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism. PLoS One (2008) 1.24

A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron (2006) 1.23

Intrinsic phenotypic differences of asthmatic epithelium and its inflammatory responses to respiratory syncytial virus and air pollution. Am J Respir Cell Mol Biol (2011) 1.22

Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins. Proc Natl Acad Sci U S A (2006) 1.21

Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci (2009) 1.18

Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res (2010) 1.17

Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res (2005) 1.16

Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell (2008) 1.15

Exercise reverses preamyloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2007) 1.12

Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest (2013) 1.12

Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromolecular Med (2007) 1.12

Drosophila models of neurodegenerative disease. NeuroRx (2005) 1.12

Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging (2006) 1.10

Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet (2008) 1.09

Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS One (2009) 1.07

Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci (2010) 1.04

Formation and propagation of tau oligomeric seeds. Front Neurol (2013) 1.04

Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03

Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol (2009) 1.02

Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry (2006) 1.02

Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiol Dis (2010) 1.02

Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies. J Biol Chem (2013) 1.01

MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 1.00

T2D-Db: an integrated platform to study the molecular basis of Type 2 diabetes. BMC Genomics (2008) 0.98

A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol (2009) 0.98

Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch Neurol (2008) 0.98

α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem (2011) 0.96

Microvesicating effects of sulfur mustard on an in vitro human skin model. Toxicol In Vitro (2009) 0.96

Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet (2014) 0.95

Pathogenic VCP/TER94 alleles are dominant actives and contribute to neurodegeneration by altering cellular ATP level in a Drosophila IBMPFD model. PLoS Genet (2011) 0.94

Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. Hum Mol Genet (2004) 0.93

Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin. Mol Neurodegener (2008) 0.93

Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. Mol Neurodegener (2012) 0.92

Hydrolethalus syndrome is caused by a missense mutation in a novel gene HYLS1. Hum Mol Genet (2005) 0.92

TDP-43 Phosphorylation by casein kinase Iε promotes oligomerization and enhances toxicity in vivo. Hum Mol Genet (2013) 0.92

Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of anti-amyloid antibodies. Exp Dermatol (2010) 0.90

LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. J Lipid Res (2004) 0.90

Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain. Brain Res (2005) 0.90

Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun (2014) 0.89

Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed) (2013) 0.89

Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis (2010) 0.89

CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. J Exp Med (2008) 0.88

Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration. J Alzheimers Dis (2010) 0.87

Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species. ACS Chem Neurosci (2014) 0.87

Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology (2010) 0.86

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun (2014) 0.85

Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. ALTEX (2012) 0.85

Poloxamer 188 copolymer membrane sealant rescues toxicity of amyloid oligomers in vitro. J Mol Biol (2009) 0.85

ApoE4-Driven Accumulation of Intraneuronal Oligomerized Aβ42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function. Int J Alzheimers Dis (2011) 0.84

Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine (2006) 0.83

Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. Biochem Biophys Res Commun (2012) 0.83

Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int J Alzheimers Dis (2009) 0.82

Characterization of Na+-permeable cation channels in LLC-PK1 renal epithelial cells. J Biol Chem (2004) 0.81